<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35315098</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical virology</Title>
          <ISOAbbreviation>J Med Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.</ArticleTitle>
        <Pagination>
          <StartPage>3006</StartPage>
          <EndPage>3016</EndPage>
          <MedlinePgn>3006-3016</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27730</ELocationID>
        <Abstract>
          <AbstractText>Broad-spectrum antiviral agents targeting viral RNA-dependent RNA polymerase (RdRp) are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 (COVID-19) pandemic and its future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. Molnupiravir is a nucleoside analog that in vivo experiments have been reported to inhibit the replication of SARS-CoV-2, the virus that causes COVID-19. Clinical trials of molnupiravir as a therapy for patients with mild-to-moderate COVID-19 also suggest its significant therapeutic efficacy in comparison to placebo. Molnupiravir is lethally mutagenic against viral RNA, but its effect on host cell DNA is being questioned. Herein, the safety concerns of molnupiravir are discussed with recent findings from published reports and clinical trials. The unchanged efficacy of molnupiravir against mutated SARS-CoV-2 variants is also highlighted. With its administration via the oral route, molnupiravir is expected to turn the tide of the COVID-19 pandemic.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Masyeni</LastName>
            <ForeName>Sri</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitas Warmadewa, Denpasar, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Sanjiwani Hospital, Gianyar, Indonesia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iqhrammullah</LastName>
            <ForeName>Muhammad</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Indonesia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frediansyah</LastName>
            <ForeName>Andri</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>National Research and Innovation Agency (BRIN), Wonosari, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Division for Natural Product Technology (BPTBA), Indonesian Institute of Sciences (LIPI), Wonosari, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nainu</LastName>
            <ForeName>Firzan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tallei</LastName>
            <ForeName>Trina</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The University Centre of Excellence for Biotechnology and Conservation of Wallacea, Institute for Research and Community Services, Sam Ratulangi University, Manado, Indonesia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emran</LastName>
            <ForeName>Talha Bin</ForeName>
            <Initials>TB</Initials>
            <Identifier Source="ORCID">0000-0003-3188-2272</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ophinni</LastName>
            <ForeName>Youdiil</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Host Defense, WPI Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhama</LastName>
            <ForeName>Kuldeep</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-7469-4752</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harapan</LastName>
            <ForeName>Harapan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-7630-8413</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Virol</MedlineTA>
        <NlmUniqueID>7705876</NlmUniqueID>
        <ISSNLinking>0146-6615</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009153" MajorTopicYN="N">Mutagens</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">EIDD-2801</Keyword>
        <Keyword MajorTopicYN="N">error catastrophe</Keyword>
        <Keyword MajorTopicYN="N">mutagenesis</Keyword>
        <Keyword MajorTopicYN="N">β-d-N4-hydroxycytidine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35315098</ArticleId>
        <ArticleId IdType="pmc">PMC9088670</ArticleId>
        <ArticleId IdType="doi">10.1002/jmv.27730</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Harrison AG, Lin T, Wang P. Mechanisms of SARS‐CoV‐2 transmission and pathogenesis. Trends Immunol. 2020;41:1100‐1115. 10.1016/j.it.2020.10.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2020.10.004</ArticleId>
            <ArticleId IdType="pmc">PMC7556779</ArticleId>
            <ArticleId IdType="pubmed">33132005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang D, Zhou M, Nie X, et al. Epidemiological characteristics and transmission model of corona virus disease 2019 in China. J Infect. 2020;80:e25‐e27. 10.1016/j.jinf.2020.03.008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinf.2020.03.008</ArticleId>
            <ArticleId IdType="pmc">PMC7118625</ArticleId>
            <ArticleId IdType="pubmed">32171870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De P, Chakraborty I, Karna B, Mazumder N. Brief review on repurposed drugs and vaccines for possible treatment of COVID‐19. Eur J Pharmacol. 2021;898:173977. 10.1016/j.ejphar.2021.173977
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2021.173977</ArticleId>
            <ArticleId IdType="pmc">PMC7905377</ArticleId>
            <ArticleId IdType="pubmed">33639193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Al‐Karmalawy AA, Soltane R, Abo Elmaaty A, et al. Coronavirus disease (COVID‐19) control between drug repurposing and vaccination: a comprehensive overview. Vaccines (Basel). 9, 2021:1317. 10.3390/vaccines9111317
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines9111317</ArticleId>
            <ArticleId IdType="pmc">PMC8622998</ArticleId>
            <ArticleId IdType="pubmed">34835248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID‐19 vaccine. Nat Med. 2021;27:225‐228. 10.1038/s41591-020-1124-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-1124-9</ArticleId>
            <ArticleId IdType="pmc">PMC7573523</ArticleId>
            <ArticleId IdType="pubmed">33082575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosiello D, Anwar S, Yufika A, et al. Acceptance of COVID‐19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America. Narra J. 2021;1:e55.</Citation>
        </Reference>
        <Reference>
          <Citation>
Wang Z, Yang L. Turning the tide: natural products and natural‐product‐inspired chemicals as potential counters to SARS‐CoV‐2 infection. Front Pharmacol. 2020;11:1013. 10.3389/fphar.2020.01013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.01013</ArticleId>
            <ArticleId IdType="pmc">PMC7343773</ArticleId>
            <ArticleId IdType="pubmed">32714193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ianevski A, Yao R, Fenstad MH, et al. Potential antiviral options against SARS‐CoV‐2 infection. Viruses. 2020;12:642. 10.3390/v12060642
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v12060642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elfiky AA. SARS‐CoV‐2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn. 2021;39:3204‐3212. 10.1080/07391102.2020.1761882
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07391102.2020.1761882</ArticleId>
            <ArticleId IdType="pmc">PMC7222627</ArticleId>
            <ArticleId IdType="pubmed">32338164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rubin D, Chan‐Tack K, Farley J, Sherwat A. FDA approval of remdesivir—a step in the right direction. N Engl J Med. 2020;383:2598‐2600. 10.1056/NEJMp2032369
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp2032369</ArticleId>
            <ArticleId IdType="pubmed">33264539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID‐19: a randomized clinical trial. JAMA. 2020;324:1048‐1057. 10.1001/jama.2020.16349
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId>
            <ArticleId IdType="pmc">PMC7442954</ArticleId>
            <ArticleId IdType="pubmed">32821939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID‐19. Curr Opin Virol. 2021;50:17‐22. 10.1016/j.coviro.2021.06.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coviro.2021.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC8277160</ArticleId>
            <ArticleId IdType="pubmed">34271264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Snead DR, Gopalsamuthiram V, Williams C, Noble J, Jamison TF, Gupton BF. A concise route to MK‐4482 (EIDD‐2801) from cytidine: part 2. Synlett. 2020;32:326‐328. 10.1055/a-1275-2848
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-1275-2848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. RNA 3'‐end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A. 2012;109:9372‐9377. 10.1073/pnas.1201130109
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1201130109</ArticleId>
            <ArticleId IdType="pmc">PMC3386072</ArticleId>
            <ArticleId IdType="pubmed">22635272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Agostini ML, Pruijssers AJ, Chappell JD, et al. Small‐molecule antiviral beta‐d‐N (4)‐hydroxycytidine inhibits a proofreading‐intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348‐19. 10.1128/JVI.01348-19
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01348-19</ArticleId>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA‐dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295:4773‐4779. 10.1074/jbc.AC120.013056
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.AC120.013056</ArticleId>
            <ArticleId IdType="pmc">PMC7152756</ArticleId>
            <ArticleId IdType="pubmed">32094225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID‐19: a systematic review of literature. Diabetes Metab Syndr. 2021;15:102329. 10.1016/j.dsx.2021.102329
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dsx.2021.102329</ArticleId>
            <ArticleId IdType="pmc">PMC8556684</ArticleId>
            <ArticleId IdType="pubmed">34742052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother. 2003;47:244‐254. 10.1128/AAC.47.1.244-254.2003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.47.1.244-254.2003</ArticleId>
            <ArticleId IdType="pmc">PMC149013</ArticleId>
            <ArticleId IdType="pubmed">12499198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoon JJ, Toots M, Lee S, et al. Orally efficacious broad‐spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62:e00766‐18. 10.1128/AAC.00766-18
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00766-18</ArticleId>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11:eaax5866 10.1126/scitranslmed.aax5866
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Imran M, Kumar Arora M, Asdaq SMB, et al. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID‐19. Molecules. 2021;26:19. 10.3390/molecules26195795
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules26195795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toots M, Plemper RK. Next‐generation direct‐acting influenza therapeutics. Transl Res. 2020;220:33‐42. 10.1016/j.trsl.2020.01.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2020.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC7102518</ArticleId>
            <ArticleId IdType="pubmed">32088166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2. EMBO Mol Med. 2021;13:e13105. 10.15252/emmm.202013105
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.202013105</ArticleId>
            <ArticleId IdType="pmc">PMC7646058</ArticleId>
            <ArticleId IdType="pubmed">33015938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jia H, Gong P. A structure‐function diversity survey of the RNA‐dependent RNA polymerases from the positive‐strand RNA viruses. Front Microbiol. 2019;10:1945. 10.3389/fmicb.2019.01945
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2019.01945</ArticleId>
            <ArticleId IdType="pmc">PMC6713929</ArticleId>
            <ArticleId IdType="pubmed">31507560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID‐19): a literature review. J Infect Public Health. 2020;13:667‐673. 10.1016/j.jiph.2020.03.019
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2020.03.019</ArticleId>
            <ArticleId IdType="pmc">PMC7142680</ArticleId>
            <ArticleId IdType="pubmed">32340833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guy RK, DiPaola RS, Romanelli F, Dutch RE. Rapid repurposing of drugs for COVID‐19. Science. 2020;368:829‐830. 10.1126/science.abb9332
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb9332</ArticleId>
            <ArticleId IdType="pubmed">32385101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication‐transcription complexes and their relevance for SARS‐CoV‐2 drug design. Nat Rev Mol Cell Biol. 2022;23:21‐39. 10.1038/s41580-021-00432-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId>
            <ArticleId IdType="pmc">PMC8613731</ArticleId>
            <ArticleId IdType="pubmed">34824452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS‐CoV‐2 mutagenesis via the RNA template. J Biol Chem. 2021;297:100770. 10.1016/j.jbc.2021.100770
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId>
            <ArticleId IdType="pmc">PMC8110631</ArticleId>
            <ArticleId IdType="pubmed">33989635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir‐induced SARS‐CoV‐2 mutagenesis. Nat Struct Mol Biol. 2021;28:740‐746. 10.1038/s41594-021-00651-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malone B, Campbell EA. Publisher correction: molnupiravir: coding for catastrophe. Nat Struct Mol Biol. 2021;28:955. 10.1038/s41594-021-00683-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41594-021-00683-6</ArticleId>
            <ArticleId IdType="pmc">PMC8504425</ArticleId>
            <ArticleId IdType="pubmed">34635834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou S, Hill CS, Sarkar S, et al. Beta‐d‐N4‐hydroxycytidine inhibits SARS‐CoV‐2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224:415‐419. 10.1093/infdis/jiab247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Naydenova K, Muir KW, Wu LF, et al. Structure of the SARS‐CoV‐2 RNA‐dependent RNA polymerase in the presence of favipiravir‐RTP. Proc Natl Acad Sci U S A. 2021;118:e2021946118. 10.1073/pnas.2021946118
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2021946118</ArticleId>
            <ArticleId IdType="pmc">PMC7896311</ArticleId>
            <ArticleId IdType="pubmed">33526596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malone B, Chen J, Wang Q, et al. Structural basis for backtracking by the SARS‐CoV‐2 replication‐transcription complex. Proc Natl Acad Sci U S A. 2021;118:e2102516118. 10.1073/pnas.2102516118
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2102516118</ArticleId>
            <ArticleId IdType="pmc">PMC8126829</ArticleId>
            <ArticleId IdType="pubmed">33883267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang Y, Li P, Solanki K, et al. Viral polymerase binding and broad‐spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology. 2021;564:33‐38. 10.1016/j.virol.2021.09.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2021.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC8486977</ArticleId>
            <ArticleId IdType="pubmed">34619630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad‐spectrum antiviral inhibits SARS‐CoV‐2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883
10.1126/scitranslmed.abb5883
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS‐CoV‐2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. 2021;6:e148003. 10.1172/jci.insight.148003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.148003</ArticleId>
            <ArticleId IdType="pmc">PMC8492301</ArticleId>
            <ArticleId IdType="pubmed">34357881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wahl A, Gralinski LE, Johnson CE, et al. SARS‐CoV‐2 infection is effectively treated and prevented by EIDD‐2801. Nature. 2021;591:451‐457. 10.1038/s41586-021-03312-w
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK‐4482/EIDD‐2801 blocks SARS‐CoV‐2 transmission in ferrets. Nat Microbiol. 2021;6:11‐18. 10.1038/s41564-020-00835-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-020-00835-2</ArticleId>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenke K, Hansen F, Schwarz B, et al. Orally delivered MK‐4482 inhibits SARS‐CoV‐2 replication in the Syrian hamster model. Nat Commun. 2021;12:2295. 10.1038/s41467-021-22580-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-22580-8</ArticleId>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ebenezer O, Jordaan MA, Ogunsakin RE, Shapi M. Potential SARS‐COV preclinical (in vivo) compounds targeting COVID‐19 main protease: a meta‐analysis and molecular docking studies. Hippokratia. 2020;24:99‐106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8256780</ArticleId>
            <ArticleId IdType="pubmed">34239286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 vaccine (CoronaVac) in healthy children and adolescents: a double‐blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;14:812‐819. 10.1016/S1473-3099(21)00319-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(21)00319-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holman W, Holman W, McIntosh S, et al. Accelerated first‐in‐human clinical trial of EIDD‐2801/MK‐4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS‐CoV‐2. Trials. 2021;22:1‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7780206</ArticleId>
            <ArticleId IdType="pubmed">33397449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS‐CoV‐2: a phase I, open‐label, dose‐escalating, randomized controlled study. J Antimicrob Chemother. 2021;76:3286‐3295. 10.1093/jac/dkab318
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkab318</ArticleId>
            <ArticleId IdType="pmc">PMC8598307</ArticleId>
            <ArticleId IdType="pubmed">34450619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad‐spectrum oral antiviral agent with activity against SARS‐CoV‐2. Antimicrob Agents Chemother. 2021;65:e02428‐20. 10.1128/AAC.02428-20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02428-20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fischer WA, JJ Eron 2nd, Holman W Jr., et al. A phase 2a clinical trial of Molnupiravir in patients with COVID‐19 shows accelerated SARS‐CoV‐2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2021;14:eabl7430. 10.1126/scitranslmed.abl7430
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abl7430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arribas JR, Bhagani S, Lobo SM. Randomized trial of molnupiravir or placebo in patients hospitalized with covid‐19. NEJM Evid. 2021;1(2). 10.1056/EVIDoa2100044
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/EVIDoa2100044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of molnupiravir for treatment of covid‐19 in nonhospitalized adults. NEJM Evid. 2021;1 (2). 10.1056/EVIDoa2100043
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/EVIDoa2100043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid‐19 in nonhospitalized patients. N Engl J Med. 2021;386:509‐520. 10.1056/NEJMoa2116044
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId>
            <ArticleId IdType="pmc">PMC8693688</ArticleId>
            <ArticleId IdType="pubmed">34914868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA‐1273 COVID‐19 vaccines in preventing SARS‐CoV‐2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020‐March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495‐500. 10.15585/mmwr.mm7013e3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.mm7013e3</ArticleId>
            <ArticleId IdType="pmc">PMC8022879</ArticleId>
            <ArticleId IdType="pubmed">33793460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mahase E. Covid‐19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422. 10.1136/bmj.n2422
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n2422</ArticleId>
            <ArticleId IdType="pubmed">34607801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merck and ridgeback biotherapeutics provide update on results from MOVe‐OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild‐to‐moderate COVID‐19. Merck. Accessed January 17th, 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>
Griffiths G, Fitzgerald R, Jaki T, et al. AGILE‐ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID‐19: a structured summary of a study protocol for a randomised platform trial. Trials. 2020;21:544. 10.1186/s13063-020-04473-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13063-020-04473-1</ArticleId>
            <ArticleId IdType="pmc">PMC7303573</ArticleId>
            <ArticleId IdType="pubmed">32560744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eloy P, Le Grand R, Malvy D, Guedj J. Combined treatment of molnupiravir and favipiravir against SARS‐CoV‐2 infection: one + zero equals two?
EBioMedicine. 2021;74:103663. 10.1016/j.ebiom.2021.103663
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2021.103663</ArticleId>
            <ArticleId IdType="pmc">PMC8577853</ArticleId>
            <ArticleId IdType="pubmed">34768087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ianevski A, Yao R, Biza S, et al. Identification and tracking of antiviral drug combinations. Viruses. 2020;12:1178. 10.3390/v12101178
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v12101178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ianevski A, Yao R, Zusinaite E, et al. Synergistic interferon‐alpha‐based combinations for treatment of SARS‐CoV‐2 and other viral infections. Viruses. 2021;13:2489. 10.3390/v13122489
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v13122489</ArticleId>
            <ArticleId IdType="pmc">PMC8705725</ArticleId>
            <ArticleId IdType="pubmed">34960758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abdelnabi R, Foo CS, Kaptein SJF, et al. The combined treatment of molnupiravir and favipiravir results in a potentiation of antiviral efficacy in a SARS‐CoV‐2 hamster infection model. EBioMedicine. 2021;72:103595. 10.1016/j.ebiom.2021.103595
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2021.103595</ArticleId>
            <ArticleId IdType="pmc">PMC8461366</ArticleId>
            <ArticleId IdType="pubmed">34571361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee J, Lee J, Kim HJ, Ko M, Jee Y, Kim S. TMPRSS2 and RNA‐dependent RNA polymerase are effective targets of therapeutic intervention for treatment of COVID‐19 caused by SARS‐CoV‐2 variants (B.1.1.7 and B.1.351). Microbiol Spectr. 2021;9:e0047221. 10.1128/Spectrum.00472-21
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/Spectrum.00472-21</ArticleId>
            <ArticleId IdType="pmc">PMC8552736</ArticleId>
            <ArticleId IdType="pubmed">34378968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir inhibits replication of the emerging SARS‐CoV‐2 variants of concern in a hamster infection model. J Infect Dis. 2021;224:749‐753. 10.1093/infdis/jiab361
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab361</ArticleId>
            <ArticleId IdType="pmc">PMC8408768</ArticleId>
            <ArticleId IdType="pubmed">34244768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szemiel AM, Merits A, Orton RJ, et al. In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS‐CoV‐2. PLoS Pathog. 2021;17:e1009929. 10.1371/journal.ppat.1009929
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009929</ArticleId>
            <ArticleId IdType="pmc">PMC8496873</ArticleId>
            <ArticleId IdType="pubmed">34534263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li P, Wang Y, Lavrijsen M, et al. SARS‐CoV‐2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:1‐3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8666617</ArticleId>
            <ArticleId IdType="pubmed">34903854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ. 2021;375:n2663. 10.1136/bmj.n2663
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n2663</ArticleId>
            <ArticleId IdType="pubmed">34737196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID‐19. Diabetes Metab Syndr. 2022;16:102396. 10.1016/j.dsx.2022.102396
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dsx.2022.102396</ArticleId>
            <ArticleId IdType="pmc">PMC8755553</ArticleId>
            <ArticleId IdType="pubmed">35051686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fact sheet for healthcare providers: emergency use authorization for molnupiravir. 2021.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
